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Purpose
Current treatment for children with polyarticular forms
of Juvenile Idiopathic Arthritis (Poly JIA) results in
approximately 50% of the patients demonstrating clini-
cally inactive disease (CID) (Wallace C, et al. J Rheumatol
2004;31:2290-4) while on treatment. Over 40% of the
children with Poly JIA are treated with a TNF antagonist
biologic often started ≤ 6 months (mos) of disease onset.
Currently we are unable to accurately predict which chil-
dren demonstrating CID while on an anti-TNF therapy
will or will not have a flare of the JIA upon discontinua-
tion of the anti-TNF agent. Anti-TNF therapy has known
short- and medium-term toxicities in children with JIA;
the long-term toxicities are unknown and the treatment
is expensive. The ultimate goal of this project is to vali-
date biomarkers that are predictive. These interim results
demonstrate clinical aspects of assessing CID and stop-
ping anti-TNF therapy.
Methods
In 12 pediatric rheumatology centers, 120 children with
Poly JIA demonstrating CID while on anti-TNF therapy
will be enrolled and followed for up to 14 mos. In those
subjects who demonstrate CID for the first 6 mos of the
study, the anti-TNF therapy will be stopped. The primary
outcome variable (POV) is disease flare within the next
8 months using a validated definition of disease flare
(Brunner HI, et al. J Rheumatol 2002;29:1058-64).
Results
Forty eight subjects were enrolled by 12/20/2010. At the
time of enrollment, the mean (median) age was 11.5 yrs
(12.4) and disease duration 5.9 yrs (4.4). JIA subtype was
Extended Oligo in 5, Poly RF negative in 38, and Poly RF
positive in 5. 20 subjects were ANA positive, 27 ANA
negative and 1 unknown. There were 35 females and 14
males; 45 were Caucasian and 3 African-American;
3 were Hispanic. Thirty eight (79%) were taking etaner-
cept, 7 (15%) adalimumab and 3 (6%) infliximab. Sixteen
(33%) were taking background methotrexate, while
32 (66%) were on anti-TNF therapy monotherapy. At the
baseline study visit, the mean (median) duration of anti-
TNF therapy was 2.2 yrs (1.5). All 48 subjects met the
criteria for CID at the base line visit. At the time of ana-
lysis, 7/48 (14%) failed to demonstrate continued CID for
the first 6 months of the study. Eighteen subjects demon-
strated CID for the first 6 mos of the study and stopped
anti-TNF therapy at the month 6 study visit. One subject
discontinued the study due to logistical reasons (reloca-
tion of the family). In the 18 subjects stopping anti-TNF
therapy, 6 (33%) have flared at a mean (median) of
56 days (28) after stopping the anti-TNF therapy. In the
12 subjects not demonstrating flare the mean (median)
time off the anti-TNF agent is 143 days (158). This study
is ongoing and the other 23 subjects have not yet com-
pleted the first 6 mos of the study.
Conclusion
In children with one of the polyarticular forms of JIA on
stable anti-TNF therapy, having achieved CID at one
visit, approximately 14% will not remain in CID for the
next 6 months. In those who stop the anti-TNF therapy,
66% have remained off the anti-TNF therapy without
demonstrating flare to date.
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